KMI169
Product Specifications
Target
Epigenetic Reader Domain
Related Pathways
Chromatin/Epigenetic
Bioactivity
KMI169 is a potent and selective bisubstrate inhibitor targeting KMT9's SAM and substrate binding pockets. KMT9 monomethylates histone H4 at lysine 12 and regulates the proliferation of prostate cancer cells. KMI169 can be utilized for research in prostate cancer.
Molecular Formula
C31H31Cl2N7O2
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15095619 1 Vial
Lentiviral human RNF20 shRNA (UAS) - Lentiviral human RNF20 shRNA (UAS, iRFP) (100)
Ask
View Details